Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $553 | In Stock | |
5 mg | $1,180 | In Stock |
Description | Marizomib (ML858) is a novel irreversible brain-permeable proteasome inhibitor that inhibits CT-L (β5), CT-T-laspase-like (C-L, β1), and trypsin-like (T-L, β2) 20S proteasomes with IC50s of 3.5, 28, and 430 nM, respectively. |
Targets&IC50 | Trypsin like:430 nM, CTL laspase-like:28 nM, CTL:3.5 nM |
In vitro | Marizomib (60 nM; 24 h; glioma cells) causes apoptosis and caspase-3 activation in glioma cells.[1] Marizomib (0.1-10000 nM; 72 h; U-251 and D-54 cells) potently decreases survival of D-54 and U-251 cells in a dose-dependent manner (IC50s: ∼52 nM for U-251 and ∼20 nM for D-54).[1] |
In vivo | Marizomib (0.15 mg/kg; i.v.; twice a week for three weeks; CB-17 SCID-male mice) obviously reduces tumor growth and is not associated with any toxicity[3]. |
Alias | NPI-0052, Salinosporamide A, ML858 |
Molecular Weight | 313.78 |
Formula | C15H20ClNO4 |
Cas No. | 437742-34-2 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 31.38 mg/mL (100 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.